FBXO11

Across TCGA pan-cancer cohorts, FBXO11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO11 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FBXO11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXO11 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where FBXO11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.139	0.979	.001	21	view →
PDAC	DFS	Quartile	II,III,IV	0.943	0.533	.003	14	view →
HNSC	DFS	Median	III,IV	0.704	0.879	.038	3	view →
LUAD	DFS	Median	III,IV	0.618	0.848	.043	3	view →
LSCC	DFS	Median	II,III,IV	0.999	0.835	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO11–CCRCC (DFS)

Open the CCRCC breakdown →